Industry stakeholders say CMS is rushing its plan to help state Medicaid programs, health plans and drugmakers create value-based arrangements for prescription drugs. The proposal also could create an administrative nightmare.
Industry wants an overhaul of CMS’ plan for Medicaid value-based drugs
